Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc. is listed today as Korsana Biosciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2023 | $5 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Jun 2021 | $18 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Jul 2020 | $24 M | No. 2 | $10 to $50 million | equity | SEC | |
| Apr 2019 | $175 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Cyclerion Therapeutics, Inc. had revenue between $1 million and $5 million when it filed its newest notice of a funding round (May 2023).
SEC Form D (revenue range) · May 2023
Revenue range over time, as stated in its notices: no revenue in 2019; revenue between $1 million and $5 million in 2020; revenue between $1 million and $5 million in 2021; revenue between $1 million and $5 million in 2023.
SEC Form D (revenue range) · May 2023
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · May 2023
Products and services#
No products or services of Cyclerion Therapeutics, Inc. are on record.
Investors#
3 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2026) | SEC Form 3 |
| Fairmount Healthcare Co-Invest VI L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2026) | SEC Form 3 |
| Fairmount Healthcare Fund II L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2026) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 49 investors.
Largest shareholders today
Institutions holding Korsana Biosciences, Inc. shares, as of Sep 30, 2026.
- Fairmount Funds Management LLC$291 M19.99%
- TCG Crossover Management, LLC$146 M9.99%
- Venrock Adviser, LLC$146 M9.99%
- FMR LLC$102 M7.03%
- Jpmorgan Chase & Co$86 M5.90%
- Fcpm III Services B.V.$70 M4.81%
- Sanofi$64 M4.38%
- Foresite Capital Management VI LLC$46 M3.14%
- General Atlantic, L.P.$44 M3.00%
- Ra Capital Management, L.P.$29 M1.96%
- Commodore Capital LP$28 M1.93%
- RTW Investments, LP$28 M1.93%
- Vivo Capital, LLC$28 M1.93%
- Janus Henderson Group Ltd.$25 M1.73%
- SR One Capital Management, LP$20 M1.35%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Anjeza M. Gjino | Executive officer | May 2023 |
| Cheryl M. Gault | Executive officer | May 2023 |
| Peter M. Hecht | Executive officer | May 2023 |
| Andreas M. Busch | Executive officer | Jun 2021 |
| Andreas E. Busch | Executive officer | Aug 2020 |
| Mark G. Currie | Executive officer | Aug 2020 |
| William G. Huyett | Executive officer | Aug 2020 |
| Errol M. De Souza | Director | May 2023 |
| Ole M. Isacson | Director | May 2023 |
| Peter M. Hecht | Director | May 2023 |
| Steven M. Hyman | Director | May 2023 |
| Terrance M. McGuire | Director | May 2023 |
| George M. Conrades | Director | Jun 2021 |
| Kevin M. Churchwell | Director | Jun 2021 |
| Marsha M. Fanucci | Director | Jun 2021 |
| Michael M. Mendelsohn | Director | Jun 2021 |
| Stephanie M. Lovell | Director | Jun 2021 |
| Amy E. Schulman | Director | Aug 2020 |
| George E. Conrades | Director | Aug 2020 |
| Kevin E. Churchwell | Director | Aug 2020 |
| Marsha E. Fanucci | Director | Aug 2020 |
| Michael E. Mendelsohn | Director | Aug 2020 |
| Ole E. Isacson | Director | Aug 2020 |
| Stephanie E. Lovell | Director | Aug 2020 |
| Terrance E. McGuire | Director | Aug 2020 |
| Amy G. Schulman | Director | Apr 2019 |
| George G. Conrades | Director | Apr 2019 |
| Kevin G. Churchwell | Director | Apr 2019 |
| Marsha G. Fanucci | Director | Apr 2019 |
| Michael G. Mendelsohn | Director | Apr 2019 |
| Ole G. Isacson | Director | Apr 2019 |
| Stephanie G. Lovell | Director | Apr 2019 |
| Terrance G. McGuire | Director | Apr 2019 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.